At Tinkeso Therapeutics, we focus on developing allogeneic cell therapy to treat T-cell driven autoimmune diseases and cancer by leveraging Nature Killer T (NKT) cells, the type of cells with the dual capabilities of T cells and Natural Killer (NK) cells.